DTILPRECISION BIOSCIENCES INCvs its industry peers
A metric-by-metric comparison of PRECISION BIOSCIENCES INC against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DTILThis | $194M#8 | 21.7x#3 | 3.7x#12 | 5.7x#5 | -50.1%#5 | -738.0%#16 | -152.2%#3 | -88.3%#11 | — | — | -6.1%#6 | — |
| FATE | $245M#1 | — | 1.6x#7 | 36.9x#8 | -51.2%#6 | 26.8%#4 | -2222.4%#9 | -88.8%#12 | -102.3%#2 | — | 62.9%#1 | — |
| CABA | $242M#2 | — | 1.2x#5 | — | — | -44.9%#12 | — | -79.7%#10 | — | — | -52.3%#11 | — |
| ALEC | $230M#3 | — | — | 10.9x#6 | -79.1%#7 | -20.2%#7 | -741.3%#7 | — | — | — | 42.1%#3 | — |
| PALI | $216M#4 | 1.9x#1 | 1.8x#8 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | -37.8%#9 | — |
| PLX | $209M#5 | 11.3x#2 | 2.9x#10 | 4.0x#4 | -1.2%#4 | -325.2%#15 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | 9.3%#5 | — |
| IKT | $208M#6 | — | 1.4x#6 | — | -100.0%#8 | -75.4%#13 | — | -31.5%#6 | — | — | -8.0%#7 | — |
| ARTV | $206M#7 | — | 0.6x#1 | — | -100.0%#8 | -28.3%#8 | — | -24.1%#4 | — | — | 12.0%#4 | — |
| ACOG | $180M#9 | — | 3.4x#11 | 17.6x#7 | — | -39.8%#11 | -221.7%#5 | -39.0%#8 | — | — | 44.0%#2 | — |
| IVVD | $172M#10 | — | 1.0x#4 | 3.2x#3 | 110.5%#1 | 69.1%#3 | -104.0%#2 | -29.0%#5 | — | — | -63.5%#12 | — |
| LIMN | $169M#11 | — | 563.0x#14 | — | — | -187.8%#14 | — | -3395.2%#14 | -170.3%#3 | — | -96.2%#15 | — |
| STRO | $157M#12 | — | — | 1.5x#1 | 65.2%#2 | 15.9%#5 | -154.5%#4 | — | — | — | -12.9%#8 | — |
| TARA | $144M#13 | — | 0.9x#3 | 48.7x#9 | — | -28.7%#9 | -2189.6%#8 | -35.6%#7 | — | — | — | — |
| CMPX | $138M#14 | — | 0.8x#2 | — | -100.0%#8 | -34.7%#10 | — | -40.0%#9 | — | — | -79.5%#14 | — |
| CHRS | $124M#15 | — | 2.0x#9 | 3.0x#2 | 59.8%#3 | 489.4%#1 | -429.5%#6 | 276.2%#1 | -351.2%#4 | — | -49.3%#10 | — |
| HUMA | $122M#16 | — | 3.9x#13 | 59.7x#10 | — | 72.5%#2 | -5306.0%#10 | -130.6%#13 | — | — | -72.4%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice